Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 3
1993 41
1994 49
1995 53
1996 87
1997 102
1998 89
1999 84
2000 75
2001 64
2002 75
2003 85
2004 58
2005 82
2006 83
2007 76
2008 78
2009 100
2010 90
2011 82
2012 76
2013 91
2014 96
2015 119
2016 95
2017 111
2018 112
2019 90
2020 9
Text availability
Article attribute
Article type
Publication date

Search Results

2,037 results
Results by year
Filters applied: . Clear all
Page 1
Pegylated Filgrastim Versus Filgrastim for Stem Cell Mobilization in Multiple Myeloma After Novel Agent Induction.
Abid MB, De Mel S, Abid MA, Yap ES, Gopalakrishnan SK, Chen Y, Yuen YC, Wong HC, Lin A, Poon LM, Koh LP, Chng WJ, Tan LK. Abid MB, et al. Clin Lymphoma Myeloma Leuk. 2018 Mar;18(3):174-179. doi: 10.1016/j.clml.2017.12.010. Epub 2018 Jan 5. Clin Lymphoma Myeloma Leuk. 2018. PMID: 29398647
A systematic literature review of the efficacy, effectiveness, and safety of filgrastim.
Dale DC, Crawford J, Klippel Z, Reiner M, Osslund T, Fan E, Morrow PK, Allcott K, Lyman GH. Dale DC, et al. Version 2. Support Care Cancer. 2018 Jan;26(1):7-20. doi: 10.1007/s00520-017-3854-x. Epub 2017 Sep 22. Support Care Cancer. 2018. PMID: 28939926 Free PMC article. Review.
Clinical Outcomes of Treatment with Filgrastim Versus a Filgrastim Biosimilar and Febrile Neutropenia-Associated Costs Among Patients with Nonmyeloid Cancer Undergoing Chemotherapy.
Schwartzberg LS, Lal LS, Balu S, Campbell K, Brekke L, DeLeon A, Elliott C, Korrer S. Schwartzberg LS, et al. J Manag Care Spec Pharm. 2018 Oct;24(10):976-984. doi: 10.18553/jmcp.2018.17447. Epub 2018 Apr 24. J Manag Care Spec Pharm. 2018. PMID: 29687743 Free article. Clinical Trial.
Risk of pulmonary toxicity of bleomycin and filgrastim.
Laprise-Lachance M, Lemieux P, Grégoire JP. Laprise-Lachance M, et al. J Oncol Pharm Pract. 2019 Oct;25(7):1638-1644. doi: 10.1177/1078155218804293. Epub 2018 Oct 14. J Oncol Pharm Pract. 2019. PMID: 30319063 Clinical Trial.
Tbo-Filgrastim: A Review in Neutropenic Conditions.
Blair HA, Scott LJ. Blair HA, et al. BioDrugs. 2016 Apr;30(2):153-60. doi: 10.1007/s40259-016-0172-7. BioDrugs. 2016. PMID: 27023705 Review.
Meta-analysis and indirect treatment comparison of lipegfilgrastim with pegfilgrastim and filgrastim for the reduction of chemotherapy-induced neutropenia-related events.
Bond TC, Szabo E, Gabriel S, Klastersky J, Tomey O, Mueller U, Schwartzberg L, Tang B. Bond TC, et al. J Oncol Pharm Pract. 2018 Sep;24(6):412-423. doi: 10.1177/1078155217714859. Epub 2017 Jun 14. J Oncol Pharm Pract. 2018. PMID: 28614980 Free PMC article. Review.
The evolution of value with filgrastim in oncology.
Cornes P, Krendyukov A. Cornes P, et al. Future Oncol. 2019 May;15(13):1525-1533. doi: 10.2217/fon-2018-0762. Epub 2019 Mar 5. Future Oncol. 2019. PMID: 30835142 Free article. Review.
[Comparison of Pegfilgrastim and Filgrastim for the Primary Prophylactic Effect for Preventing Febrile Neutropenia in Patients Undergoing Rituximab with Dose-adjusted EPOCH Chemotherapy].
Kataoka T, Sakurashita H, Taogoshi T, Nishigakiuchi R, Murase T, Izumitani S, Saeki Y, Matsuo H. Kataoka T, et al. Yakugaku Zasshi. 2019;139(4):629-633. doi: 10.1248/yakushi.18-00101. Yakugaku Zasshi. 2019. PMID: 30930398 Free article. Japanese.
Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia.
McBride A, Campbell K, Bikkina M, MacDonald K, Abraham I, Balu S. McBride A, et al. J Med Econ. 2017 Oct;20(10):1083-1093. doi: 10.1080/13696998.2017.1358173. Epub 2017 Aug 4. J Med Econ. 2017. PMID: 28722494
2,037 results
Jump to page
Feedback